$PIII
P3 Health Partners Inc.

2021 Q1 Form 10-Q Financial Statement

#000119312521171625 Filed on May 25, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4
Revenue $151.3M $124.9M
YoY Change
Cost Of Revenue $137.3M
YoY Change
Gross Profit -$12.38M
YoY Change
Gross Profit Margin -9.91%
Selling, General & Admin $15.33M $17.49M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $332.5K $181.8K
YoY Change
% of Gross Profit
Operating Expenses $480.0K -$1.564M
YoY Change
Operating Profit -$482.2K -$10.81M
YoY Change
Interest Expense -$3.093M
YoY Change
% of Operating Profit
Other Income/Expense, Net $5.301M -$290.7K
YoY Change
Pretax Income $4.820M -$14.20M
YoY Change
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings $4.819M -$13.34M
YoY Change
Net Earnings / Revenue 3.19% -10.68%
Basic Earnings Per Share
Diluted Earnings Per Share $124.3K -$54.76K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.290M
YoY Change
Cash & Equivalents $1.285M $179.5K
Short-Term Investments
Other Short-Term Assets $160.0K
YoY Change
Inventory
Prepaid Expenses $162.2K $215.4K
Receivables
Other Receivables $146.1K
Total Short-Term Assets $1.448M $395.0K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $6.151M
YoY Change
Goodwill $871.1K
YoY Change 17.54%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $316.3M
YoY Change
Total Long-Term Assets $316.3M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.448M $395.0K
Total Long-Term Assets $316.3M $0.00
Total Assets $317.7M $395.0K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $118.8K $2.286K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $89.99K
YoY Change
Total Short-Term Liabilities $175.6K $372.2K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $45.39M
YoY Change
Other Long-Term Liabilities $5.840M
YoY Change
Total Long-Term Liabilities $5.840M $55.34M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $175.6K $372.2K
Total Long-Term Liabilities $5.840M $55.34M
Total Liabilities $6.013M $372.2K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $4.817M -$2.286K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.000M $22.71K
YoY Change
Total Liabilities & Shareholders Equity $317.7M $395.0K
YoY Change

Cashflow Statement

Concept 2021 Q1 2020 Q4
OPERATING ACTIVITIES
Net Income $4.819M -$13.34M
YoY Change
Depreciation, Depletion And Amortization $332.5K $181.8K
YoY Change
Cash From Operating Activities -$293.5K -$17.95M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $656.2K -$694.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$316.3M -$575.7K
YoY Change
Cash From Investing Activities -$316.3M -$1.270M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 317.6M 34.78M
YoY Change
NET CHANGE
Cash From Operating Activities -293.5K -17.95M
Cash From Investing Activities -316.3M -1.270M
Cash From Financing Activities 317.6M 34.78M
Net Change In Cash 1.106M 15.56M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$293.5K -$17.95M
Capital Expenditures $656.2K -$694.0K
Free Cash Flow -$949.7K -$17.26M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Cash
Cash
1285361
CY2020Q4 us-gaap Cash
Cash
179512
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
162206
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
215448
CY2021Q1 us-gaap Assets Current
AssetsCurrent
1447567
CY2020Q4 us-gaap Assets Current
AssetsCurrent
394960
CY2021Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
316250000
CY2021Q1 us-gaap Assets
Assets
317697567
CY2020Q4 us-gaap Assets
Assets
394960
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
118786
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2286
CY2021Q1 nasd Accrued Offering Costs Current
AccruedOfferingCostsCurrent
56826
CY2020Q4 nasd Accrued Offering Costs Current
AccruedOfferingCostsCurrent
94960
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
275000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
175612
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
372246
CY2021Q1 nasd Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
5837625
CY2021Q1 us-gaap Liabilities
Liabilities
6013237
CY2020Q4 us-gaap Liabilities
Liabilities
372246
CY2021Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
306684320
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
182370
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24209
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4816670
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2286
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
5000010
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
22714
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
317697567
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
394960
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
482211
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-482211
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5301167
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5301167
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
4818956
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
298798535
CY2021Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
-306684320
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5301167
CY2021Q1 nasd Transaction Costs Associated With Initial Public Offering
TransactionCostsAssociatedWithInitialPublicOffering
234419
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
162206
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
116500
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-293498
CY2021Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
316250000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-316250000
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
309924999
CY2021Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8325000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
325652
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
317649347
CY2021Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1105849
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179512
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1285361
CY2021Q1 nasd Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
56826
CY2021Q1 nasd Initial Classification Of Classa Common Stock Subject To Possible Redemption
InitialClassificationOfClassaCommonStockSubjectToPossibleRedemption
301630950
CY2021Q1 nasd Change In Value Of Classa Common Stock Subject To Possible Redemption
ChangeInValueOfClassaCommonStockSubjectToPossibleRedemption
5053370
CY2021Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-08-20
CY2021Q1 nasd Stock Issuance Costs
StockIssuanceCosts
6827967
CY2021Q1 us-gaap Expense Related To Distribution Or Servicing And Underwriting Fees
ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
6325000
CY2021Q1 nasd Other Offering Costs
OtherOfferingCosts
502967
CY2021Q1 nasd Restricted Investments Term
RestrictedInvestmentsTerm
P185D
CY2021Q1 us-gaap Share Price
SharePrice
10.00
CY2021Q1 nasd Percentage Of Redeeming Shares Of Public Shares Without The Companys Prior Written Consent
PercentageOfRedeemingSharesOfPublicSharesWithoutTheCompanysPriorWrittenConsent
0.15
CY2021Q1 nasd Percentage Of Public Shares To Be Redeemed On Non Completion Of Business Combination
PercentageOfPublicSharesToBeRedeemedOnNonCompletionOfBusinessCombination
1.00
CY2021Q1 nasd Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
11138792
CY2021Q1 nasd Minimum Percentage Of Outstanding Single Class Stockholders Required To Accept Tender
MinimumPercentageOfOutstandingSingleClassStockholdersRequiredToAcceptTender
0.50
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
0.00
CY2021Q1 nasd Nonredeemable Net Income
NonredeemableNetIncome
4818956
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2021Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q1 nasd Percentage Of Underwriting Fee On Ipo Proceeds
PercentageOfUnderwritingFeeOnIpoProceeds
0.035
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Foresight Acquisition Corp.
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2992794
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Shell Company
EntityShellCompany
true
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-40033
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
233 Michigan Avenue
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60601
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.05
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.03
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
200000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
10800000
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
10857917
CY2021Q1 dei City Area Code
CityAreaCode
312
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
882-8897
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001832511
CY2021Q1 nasd Common Stock Threshold Percentage On Conversion Of Shares After Completion Of Ipo
CommonStockThresholdPercentageOnConversionOfSharesAfterCompletionOfIpo
0.20
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
100000
CY2021Q1 nasd Income And Franchise Tax
IncomeAndFranchiseTax
0
CY2021Q1 nasd Net Earnings
NetEarnings
0

Files In Submission

Name View Source Status
0001193125-21-171625-index-headers.html Edgar Link pending
0001193125-21-171625-index.html Edgar Link pending
0001193125-21-171625.txt Edgar Link pending
0001193125-21-171625-xbrl.zip Edgar Link pending
d197839d10q.htm Edgar Link pending
d197839dex311.htm Edgar Link pending
d197839dex312.htm Edgar Link pending
d197839dex321.htm Edgar Link pending
d197839dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nasd-20210331.xml Edgar Link completed
nasd-20210331.xsd Edgar Link pending
nasd-20210331_cal.xml Edgar Link unprocessable
nasd-20210331_def.xml Edgar Link unprocessable
nasd-20210331_lab.xml Edgar Link unprocessable
nasd-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending